Related Experiment Video
Updated: Jun 5, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
ROS Cascade-Amplified Polymeric Nanosystem Exhibiting Multi-Pathway Induction of Immunogenic Cell Death and
Hao Zhang1, Yining Wang1, Lujing Li2
1Scientific Research Center, Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, P. R. China.
Abstract:
Immunotherapy and chemotherapy for tumors still confront significant obstacles, which call for the creation of new potent treatment approaches. One promising strategy to improve anticancer immune responses is to induce immunogenic cell death (ICD) in tumor cells. However, currently available ICD-inducing agents are limited by several factors, including homogeneous mechanisms of action, low induction efficiency, and complex preparation or administration procedures. To improve ICD induction, particularly in immunologically "cold" tumors, this study proposes a drug co-delivery system designed to achieve effective chemotherapy and multi-pathway ICD induction, thereby enhancing antitumor immunity and improving the efficacy of chemoimmunotherapy. Specifically, a poly(podophyllotoxin)-based polymer was engineered to encapsulate the carbon monoxide (CO) prodrug COP, followed by surface modification with D-α-tocopheryl polyethylene glycol succinate, a stabilizing agent that promotes reactive oxygen species (ROS) generation. This design yielded a ROS cascade-amplified drug delivery platform for chemoimmunotherapy. Damage-associated molecular patterns (DAMPs) were released when ROS, CO, and podophyllotoxin combined to trigger ICD in cancer cells. Subsequently, these DAMPs facilitated the activation and maturation of dendritic cells, which then attracted cytotoxic T lymphocytes, thereby amplifying antitumor immune responses and improving treatment results.
Insights
This study developed a novel drug delivery system to enhance cancer immunotherapy. The platform effectively induces immunogenic cell death (ICD) and boosts antitumor immune responses, improving chemoimmunotherapy outcomes.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Drug Delivery Systems
Background:
- Chemotherapy and immunotherapy for tumors face challenges requiring novel treatment strategies.
- Inducing immunogenic cell death (ICD) is a promising approach to enhance anticancer immune responses.
- Current ICD inducers have limitations like low efficiency and complex administration, especially for "cold" tumors.
Purpose of the Study:
- To develop an advanced drug co-delivery system for effective chemotherapy and multi-pathway ICD induction.
- To enhance antitumor immunity and improve chemoimmunotherapy efficacy, particularly in "cold" tumors.
- To create a reactive oxygen species (ROS) cascade-amplified platform for cancer treatment.
Main Methods:
- Engineered a poly(podophyllotoxin)-based polymer to encapsulate a carbon monoxide (CO) prodrug (COP).
- Surface-modified the platform with D-α-tocopheryl polyethylene glycol succinate to promote ROS generation.
- Investigated the combined effect of ROS, CO, and podophyllotoxin in triggering ICD and releasing damage-associated molecular patterns (DAMPs).
Main Results:
- The developed platform successfully induced ICD in cancer cells through a ROS cascade amplification.
- Released DAMPs activated dendritic cells, attracting cytotoxic T lymphocytes to the tumor site.
- Demonstrated enhanced antitumor immunity and improved treatment outcomes in chemoimmunotherapy.
Conclusions:
- The ROS cascade-amplified drug delivery platform offers a potent strategy for chemoimmunotherapy.
- This approach effectively overcomes limitations of current ICD inducers, especially for "cold" tumors.
- The system holds promise for improving cancer treatment by enhancing immune responses and therapeutic efficacy.
